March 18, 2021– One of the quieter debates around the 340B drug pricing program is percolating on Capitol Hill as lawmakers consider whether to plug a loophole in the law that costs rural hospitals much-needed resources. Members of Congress from both parties are looking to pass legislation to make a change on this issue. And a recent study in the prestigious journal Health … [Read more...]
340B Providers Contemplate the Challenges Met and Prepare for the Ones Ahead
By Maureen Testoni March 11, 2021– In this pandemic-focused world we all find ourselves in, it seems only fitting that one of my highlights of this past month was getting the chance to meet Fauci. No, I’m not talking about the esteemed Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has become a household name over the past … [Read more...]
Drug Giant’s Revenues Soar While 340B Cuts Sting
February 10, 2021– While hospitals across the country have been struggling to stay afloat and serve the health needs of a nation during a historic pandemic, one of the largest drug companies in the U.S. has been boosting its already huge profits by denying safety-net providers the drug discounts that the 340B drug pricing program requires. Two new reports show that as drug … [Read more...]
340B Hospitals Are Key to the Pursuit of Health Equity
February 8, 2021– A global pandemic, an economic recession, and social strife in communities across the nation have cast a bright light on the deep racial and ethnic inequities in the U.S., starting a national dialogue that aspires to put us on a path toward real change. President Biden and his administration have made pursuing equity in health care and many other areas of our … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
Government Opinion Paves the Way for Reversal of Drug Company Refusals to Provide 340B Discounts
Jan. 8, 2021– While many of us were preparing for an untraditional New Year’s Eve celebration, the federal government made a vitally important announcement about 340B. The administration unequivocally stated that drug companies denying 340B discounts to hospitals, health centers, and clinics that partner with community pharmacies are in violation of federal law. In an … [Read more...]
Safety-Net Hospitals Launch the Beginning of the End of COVID-19
December 30, 2020– Americans and people around the world are marking the end of 2020 with glimmers of optimism as they observe the beginning of what will be a monumental immunization campaign against COVID-19. Safety-net hospitals, including many of those participating in the 340B drug pricing program, already are playing an important role in the U.S. effort. These hospitals … [Read more...]